Burghardt M. Wittig

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Cell and gene therapy in Germany: three decades of advanced technologies.

Cell and gene therapy in Germany: three decades of advanced technologies.

Journal: Immunotherapy

Published: August 19, 2025

Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.

Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.

Journal: Scandinavian journal of rheumatology

Published: July 18, 2019

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.

Journal: Oncoimmunology

Published: June 21, 2019

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.

Journal: EBioMedicine

Published: May 01, 2019

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.

Journal: AIDS (London, England)

Published: April 02, 2019

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 24, 2018

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: August 23, 2018

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.

Journal: Mucosal immunology

Published: March 27, 2017

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 03, 2017

Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis.

Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis.

Journal: Mucosal immunology

Published: April 29, 2016

Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.

Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.

Journal: Immunity, inflammation and disease

Published: February 12, 2016

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.

Journal: Molecular therapy oncolytics

Published: August 14, 2015

Showing 1-12 of 24

Last Updated: 09/26/2026